|
1
|
Mittal S and El-Serag HB: Epidemiology of
hepatocellular carcinoma: Consider the population. J Clin
Gastroenterol. 47 Suppl:S2–S6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chapiro J and Geschwind JF: Hepatocellular
carcinoma: Have we finally found the ultimate staging system for
HCC? Nat Rev Gastroenterol Hepatol. 11:334–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shao Y, Zhu B, Zheng R, Zhao X, Yin P, Lu
X, Jiao B, Xu G and Yao Z: Development of urinary pseudotargeted
LC-MS-based metabolomics method and its application in
hepatocellular carcinoma biomarker discovery. J Proteome Res.
14:906–916. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou L, Ding L, Yin P, Lu X, Wang X, Niu
J, Gao P and Xu G: Serum metabolic profiling study of
hepatocellular carcinoma infected with hepatitis B or hepatitis C
virus by using liquid chromatography-mass spectrometry. J Proteome
Res. 11:5433–5442. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Steinfath M, Groth D, Lisec J and Selbig
J: Metabolite profile analysis: From raw data to regression and
classification. Physiol Plant. 132:150–161. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pham-Tuan H, Kaskavelis L, Daykin CA and
Janssen HG: Method development in high-performance liquid
chromatography for high-throughput profiling and metabonomic
studies of biofluid samples. J Chromatogr B Analyt Technol Biomed
Life Sci. 789:283–301. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Katajamaa M and Oresic M: Processing
methods for differential analysis of LC/MS profile data. BMC
Bioinformatics. 6:1792005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang
W, Lu X, Yang S, Gu J and Xu G: A metabonomic study of hepatitis
B-induced liver cirrhosis and hepatocellular carcinoma by using
RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst.
5:868–876. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen J, Zhao X, Fritsche J, Yin P,
Schmitt-Kopplin P, Wang W, Lu X, Häring HU, Schleicher ED, Lehmann
R and Xu G: Practical approach for the identification and isomer
elucidation of biomarkers detected in a metabonomic study for the
discovery of individuals at risk for diabetes by integrating the
chromatographic and mass spectrometric information. Anal Chem.
80:1280–1289. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sumner LW, Amberg A, Barrett D, Beale MH,
Beger R, Daykin CA, Fan TW, Fiehn O, Goodacre R, Griffin JL, et al:
Proposed minimum reporting standards for chemical analysis Chemical
Analysis Working Group (CAWG) Metabolomics Standards Initiative
(MSI). Metabolomics. 3:211–221. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dunn WB, Broadhurst D, Brown M, Baker PN,
Redman CW, Kenny LC and Kell DB: Metabolic profiling of serum using
ultra performance liquid chromatography and the LTQ-Orbitrap mass
spectrometry system. J Chromatogr B Analyt Technol Biomed Life Sci.
871:288–298. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Funk ML, Rosenberg DM and Lok AS:
World-wide epidemiology of HBeAg-negative chronic hepatitis B and
associated precore and core promoter variants. J Viral Hepat.
9:52–61. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tan Y, Yin P, Tang L, Xing W, Huang Q, Cao
D, Zhao X, Wang W, Lu X, Xu Z, et al: Metabolomics study of
stepwise hepatocarcinogenesis from the model rats to patients:
Potential biomarkers effective for small hepatocellular carcinoma
diagnosis. Mol Cell Proteomics. 11:M111.0106942012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao H, Huang H, Xu W, Chen D, Yu J, Li J
and Li L: Fecal metabolome profiling of liver cirrhosis and
hepatocellular carcinoma patients by ultra performance liquid
chromatography-mass spectrometry. Anal Chim Acta. 691:68–75. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Taylor LA, Arends J, Hodina AK, Unger C
and Massing U: Plasma lyso-phosphatidylcholine concentration is
decreased in cancer patients with weight loss and activated
inflammatory status. Lipids Health Dis. 6:172007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan JJ, Jung JS, Lee JE, Lee J, Huh SO,
Kim HS, Jung KC, Cho JY, Nam JS, Suh HW, et al: Therapeutic effects
of lysophosphatidylcholine in experimental sepsis. Nat Med.
10:161–167. 2004. View
Article : Google Scholar : PubMed/NCBI
|
